Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

被引：0
|
作者：
Taguchi, Satoru [1 ]
Kawai, Taketo [2 ]
Nakagawa, Tohru [2 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Dept Urol, Tokyo, Japan
来源：
BJU INTERNATIONAL | 2024年 / 134卷 / 01期
关键词：
D O I：
10.1111/bju.16245
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 44
页数：2
相关论文
共 50 条
  • [31] Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study
    Minato, Akinori
    Furubayashi, Nobuki
    Harada, Mirii
    Negishi, Takahito
    Sakamoto, Naotaka
    Song, Yoohyun
    Hori, Yoshifumi
    Tomoda, Toshihisa
    Tamura, Shingo
    Kuroiwa, Kentaro
    Seki, Narihito
    Tomisaki, Ikko
    Harada, Kenichi
    Nakamura, Motonobu
    Fujimoto, Naohiro
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 499.e1 - 499.e8
  • [32] Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
    Sekito, Takanori
    Bekku, Kensuke
    Katayama, Satoshi
    Watanabe, Tomofumi
    Tsuboi, Ichiro
    Yoshinaga, Kasumi
    Maruyama, Yuki
    Yamanoi, Tomoaki
    Kawada, Tatsushi
    Tominaga, Yusuke
    Sadahira, Takuya
    Iwata, Takehiro
    Nishimura, Shingo
    Kusumi, Norihiro
    Edamura, Kohei
    Kobayashi, Tomoko
    Kurose, Kyohei
    Ichikawa, Takaharu
    Miyaji, Yoshiyuki
    Wada, Koichiro
    Kobayashi, Yasuyuki
    Araki, Motoo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (04)
  • [33] Pembrolizumab Retreatment: Lessons from a Selected Group of Patients with Urothelial Carcinoma
    Zugman, Miguel
    Nguyen, Charles B.
    EUROPEAN UROLOGY, 2025, 87 (04) : 396 - 397
  • [34] A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)
    Hussain, Maha H. A.
    Kocherginsky, Masha
    Singh, Parminder
    Tan, Winston
    Myint, Zin
    Jiang, Di
    Wulff-Burchfield, Elizabeth Marie
    Ma, Yangruijue
    Sharon, Elad
    Piekarz, Richard
    Meeks, Joshua J.
    VanderWeele, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape
    Brown, Jason R.
    Koshkin, Vadim S.
    EUROPEAN UROLOGY FOCUS, 2024, 10 (02): : 231 - 233
  • [36] The biological impacts of CEBPD on urothelial carcinoma development and progression
    Chan, Ti-Chun
    Shiue, Yow-Ling
    Li, Chien-Feng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] Autophagy: Friend or Foe for Progression and Treatment of Urothelial Carcinoma
    Balaji, K. C.
    JOURNAL OF UROLOGY, 2014, 191 (06): : 1644 - 1645
  • [38] Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
    Hayakawa, Nozomi
    Kikuchi, Eiji
    Suzuki, Shigeaki
    Oya, Mototsugu
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2020, 9 (03) : 123 - 126
  • [39] Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases
    Sugihara, Yuriko
    Kawai, Taketo
    Yamada, Daisuke
    Furuyama, Chiaki
    Sato, Yusuke
    Kume, Haruki
    EUROPEAN JOURNAL OF CANCER, 2020, 126 : 91 - 92
  • [40] Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma
    Okada, Hirofumi
    Kamiya, Koji
    Murata, Satoru
    Sugihara, Toru
    Sato, Atsuko
    Maekawa, Takeo
    Komine, Mayumi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2020, 47 (09): : E321 - E322
12345